#Sweden #Stockholm #Nevisense #SciBase #Bergh Securities

SciBase Announces Rights Issue

On January 9, 2026, SciBase Holding AB, the innovative healthcare technology company, made an important announcement regarding its latest financial maneuver aimed at fostering growth and innovation. The Board of Directors confirmed the initiation of a rights issue expected to raise approximately SEK 83 million. This considerable financial effort underscores SciBase's commitment to enhancing its operations in dermatological diagnostics, particularly with its flagship product, Nevisense.

The rights issue, ratified by the company’s board on December 29, 2025, is designed to fortify the capital base of SciBase, enabling the company to invest further in research and development. This focus aligns with SciBase's mission to deliver cutting-edge solutions for early skin cancer detection, an area that could greatly benefit from additional funding and technological advancements.

Information Document & Accessibility

To ensure transparency and regulatory compliance, the information document associated with this rights issue has been officially registered with the Swedish Financial Supervisory Authority and made accessible through both SciBase's website and the website of Bergs Securities. Investors are encouraged to review this document to gain comprehensive insights into the rights issue’s terms and conditions.

For those interested, the application forms necessary to participate in this rights issue are also available online. This process is set to start with the trading of subscription rights from January 12 until January 21, 2026, followed by the subscription period that extends from January 12 to January 26, 2026.

Key Dates

Here's a brief timeline to help potential investors keep track of important dates regarding the rights issue:

• - Trading in Subscription Rights: January 12 - 21, 2026
• - Subscription Period: January 12 - 26, 2026
• - Trading in Paid Subscribed Shares (BTA): January 12 - February 13, 2026
• - Outcome Announcement Date: January 27, 2026

This structured approach not only facilitates participation from existing shareholders but also encourages new investors by establishing a clear framework surrounding the rights issue.

Strategic Advisors

To navigate this capital raise effectively, SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisors, while the legal intricacies are being handled by Advokatfirman Schjødt. Their expertise is anticipated to streamline the process and ensure it conforms to existing financial regulations across jurisdictions.

About SciBase and Nevisense

SciBase is not just a name in the medical technology sector; it represents a commitment to innovation. The company's flagship product, Nevisense, is a notable breakthrough in the field of dermatology, integrating artificial intelligence (AI) with electrical impedance spectroscopy (EIS) to yield more accurate diagnostic results for skin health management. This early detection capability is crucial for decreasing patient suffering and ultimately saving lives through timely interventions.

With over two decades of foundational research at the prestigious Karolinska Institutet in Stockholm, SciBase stands at the forefront of dermatological advancements. Listed on the Nasdaq First North Growth Market since June 2, 2015, the firm is keen on improving healthcare outcomes while reducing associated costs, reflecting its broader objectives within the healthcare landscape.

As this rights issue unfolds, potential investors and stakeholders in the medical technology sector will undoubtedly watch with keen interest. The funds raised are expected to propel SciBase further into its goal of enhancing healthcare accessibility and efficacy through innovative dermatological solutions. For continuous updates, financial reports, and press releases, stakeholders are to visit SciBase's official investor relations page at SciBase Investors.

In an ever-evolving market characterized by rapid technological progress, initiatives like SciBase's rights issue not only prepare companies for their next growth stage but also signify their resolve in fostering advancements that benefit patients globally.